Verteporfin photodynamic therapy for neovascular age-related ...
Verteporfin photodynamic therapy for neovascular age-related ... Verteporfin photodynamic therapy for neovascular age-related ...
84 References16. Stelmack J. Quality of life of low-vision patients and outcomes of low-vision rehabilitation.Optom Vis Sci 2001;78:335–42.17. Margolis MK, Coyne K, Kennedy-Martin T, Baker T, Schein O, Revicki DA. Vision-specificinstruments for the assessment of health-related quality of life and visual functioning: aliterature review. Pharmacoeconomics 2002;20:791–812.18. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related maculardegeneration. Arch Ophthalmol 2000;118:47–51.19. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanibfor the treatment of age-related macular degeneration: a systematic review and economicevaluation. Health Technol Assess 2008;12(16).20. Harding SP, Tomlin K, Reeves BC, Langham J, Walker J, Carpenter J, et al. Verteporfinphotodynamic therapy cohort study: report 1: effectiveness and factors influencingoutcomes. Ophthalmology 2009;116:e1–8.21. Grieve R, Guerriero C, Walker J, Tomlin K, Langham J, Harding S, et al. Verteporfinphotodynamic therapy cohort study: report 3: cost effectiveness and lessons for futureevaluations. Ophthalmology 2009;116:2471–7.22. Reeves BC, Langham J, Walker J, Grieve R, Chakravarthy U, Tomlin K, et al. Verteporfinphotodynamic therapy cohort study: report 2: clinical measures of vision and health-relatedquality of life. Ophthalmology 2009;116:2463–70.23. Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, et al. Economic burden ofbilateral neovascular age-related macular degeneration: multi-country observational study.Pharmacoeconomics 2008;26:57–73.24. Garattini L, Castelnuovo E, Lanzetta P, Viscarra C, Ricci E, Parazzini F, et al. Direct medicalcosts of age-related macular degeneration in italian hospital ophthalmology departments. Amulticenter, prospective 1-year study. Eur J Health Econ 2004;5:22–7.25. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerlandand cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol2001;16:218–22.26. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness andcost-utility of photodynamic therapy for wet age-related macular degeneration: a systematicreview and economic evaluation. Health Technol Assess 2003;7(9).27. Stirling B, Shoshanna S, Taryn S, Gold M. Has the time come for cost-effectiveness analysisin US health care? Health Econ Pol Law 2009;4:425–43.28. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost–utility of photodynamictherapy in eyes with neovascular macular degeneration – a value-based reappraisal with5-year data. Am J Ophthalmol 2005;140:679–87.29. Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, et al. Identifyingand valuing outcomes. In Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Costeffectivenessin health and medicine. New York, NY; Oxford University Press; 1996. pp.82–134.30. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) StudyGroup. Verteporfin therapy of subfoveal choroidal neovascularization in patients with agerelated macular degeneration: additional information regarding baseline lesion composition’simpact on vision outcomes. TAP report no. 3. Arch Ophthalmol 2002;120:1443–54.31. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc 1999;97:473–511.
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 68532. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87:1201–4.33. Wright SE, Keeffe JE, Thies LS. Direct costs of blindness in australia. Clin Exp Ophthalmol2000;28:140–2.34. Hart PM, Chakravarthy U, Mackenzie G, Chisholm IH, Bird AC, Stevenson MR, et al. Visualoutcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapyfor age-related macular degeneration. Arch Ophthalmol 2002;120:1029–38.35. Ali F, Chan WC, Stevenson MR, Muldrew KA, Chakravarthy U. Morphometric analysisof angiograms of exudative lesions in age-related macular degeneration. Arch Ophthalmol2004;122:710–15.36. Hogg R, Curry E, Muldrew A, Winder J, Stevenson M, McClure M, et al. Identification oflesion components that influence visual function in age-related macular degeneration. Br JOphthalmol 2003;87:609–14.37. Verteporfin Roundtable 2000 and 2001 Participants. Treatment of age-related maculardegeneration with photodynamic therapy (TAP) study group principal investigators;Verteporfin in photodynamic therapy (VIP) study group principal investigators.Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidalneovascularization due to age-related macular degeneration and other causes. Retina2002;22:6–18.38. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment DiabeticRetinopathy Study design and baseline patient characteristics: ETDRS Report Number 7.Ophthalmology 1991;98:741–56.39. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrastsensitivity. Clin Vis Sci 1988;2:187–99.40. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36):I.Conceptual framework and item selection. Med Care 1992;30:473–83.41. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In Higgins JPT, Green S,editors. Cochrane handbook for systematic reviews of interventions. Chichester: John Wiley;2008. pp. 187–242. URL: www.cochrane-handbook.org (accessed 31 August 2010).42. Stevenson MR, Hart PM, Chakravarthy U, Mackenzie G, Bird AC, Owens SL, et al. Subfovealradiotherapy study. Visual functioning and quality of life in a randomised controlled clinicaltrial SFRADS report 2. Br J Ophthalmol 2005;89:1045–51.43. Desai P, Minassian DC, Reidy A. National cataract survey 1997–8: a report of the results ofthe clinical outcomes. Br J Ophthalmol 1999;83:1336–40.44. Browne JP, Hopkins C, Slack R, Topham J, Reeves BC, Lund V, et al. Health-related quality oflife after polypectomy with and without additional surgery. Laryngoscope 2006;116:297–302.45. Langham J, Reeves BC, Lindsay KW, van der Meulen JH, Kirkpatrick PJ, Gholkar AR, et al.Variation in outcome after subarachnoid hemorrhage: a study of neurosurgical units in UKand Ireland. Stroke 2009;40:111–18.46. Maguire MG, Klein ML, Chamberlin JA. Recurrent choroidal neovascularization after argonlaser photocoagulation for neovascular maculopathy. Macular Photocoagulation StudyGroup. Arch Ophthalmol 1986;104:503–12.47. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration andsmoking. The Rotterdam Study. Arch Ophthalmol 1996;114:1193–6.48. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-relatedmacular degeneration: a review of association. Eye 2005;19:935–44.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
- Page 48 and 49: 34 Key changes to the protocolsites
- Page 52 and 53: 38 Results (1) - study cohortTABLE
- Page 54 and 55: 40 Results (1) - study cohortTABLE
- Page 56 and 57: 42 Results (1) - study cohortTABLE
- Page 58 and 59: 44 Results (1) - study cohortTABLE
- Page 60 and 61: 46 Results (2) - objectives A, B, C
- Page 62 and 63: 48 Results (2) - objectives A, B, C
- Page 64 and 65: 50 Results (2) - objectives A, B, C
- Page 66 and 67: 52 Results (2) - objectives A, B, C
- Page 69 and 70: DOI: 10.3310/hta16060Health Technol
- Page 71 and 72: DOI: 10.3310/hta16060Health Technol
- Page 73 and 74: DOI: 10.3310/hta16060Health Technol
- Page 75 and 76: DOI: 10.3310/hta16060Health Technol
- Page 77: DOI: 10.3310/hta16060Health Technol
- Page 80 and 81: 66 Discussion of resultsStrengths a
- Page 82 and 83: 68 Discussion of resultsThe VPDT st
- Page 84 and 85: 70 Discussion of resultsOur analyse
- Page 86 and 87: 72 Discussion of resultsA further c
- Page 88 and 89: 74 Discussion of resultsVPDT. It is
- Page 91 and 92: DOI: 10.3310/hta16060Health Technol
- Page 93 and 94: DOI: 10.3310/hta16060Health Technol
- Page 95: DOI: 10.3310/hta16060Health Technol
- Page 100 and 101: 86 References49. Guymer RH, Chiu AW
- Page 102 and 103: 88 References83. Margrain TH. Minim
- Page 104 and 105: 90 Appendix 1THE VERTEPORFIN PHOTOD
- Page 106 and 107: 92 Appendix 11. Overview of Manual
- Page 108 and 109: 94 Appendix 1And, if also collectin
- Page 110 and 111: 96 Appendix 1more patients in the v
- Page 112 and 113: 98 Appendix 12.4 Limitations of the
- Page 114 and 115: 100 Appendix 1Box 2 Key advantages
- Page 116 and 117: 102 Appendix 14. Study population4.
- Page 118 and 119: 104 Appendix 15. Recruitment to the
- Page 120 and 121: 106 Appendix 16. Background data co
- Page 122 and 123: 108 Appendix 1Table 1: Schedule of
- Page 124 and 125: 110 Appendix 1The Verteporfin Photo
- Page 126 and 127: 112 Appendix 1• Additional clinic
- Page 128 and 129: 114 Appendix 18. Recording adverse
- Page 130 and 131: 116 Appendix 1level of benefit from
- Page 132 and 133: 118 Appendix 1• comparison of num
- Page 134 and 135: 120 Appendix 110.6 Sub-group analys
- Page 136 and 137: 122 Appendix 112. Data issues12.1 D
- Page 138 and 139: 124 Appendix 113. Organisation13.1
- Page 140 and 141: 126 Appendix 114. References[1] Ref
- Page 142 and 143: 128 Appendix 1Barnes RM, Gee L, Tay
- Page 144 and 145: 130 Appendix 1Appendix 1: Classifyi
- Page 146 and 147: 132 Appendix 1Liverpool re-treatmen
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 68532. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87:1201–4.33. Wright SE, Keeffe JE, Thies LS. Direct costs of blindness in australia. Clin Exp Ophthalmol2000;28:140–2.34. Hart PM, Chakravarthy U, Mackenzie G, Chisholm IH, Bird AC, Stevenson MR, et al. Visualoutcomes in the subfoveal radio<strong>therapy</strong> study: a randomized controlled trial of tele<strong>therapy</strong><strong>for</strong> <strong>age</strong>-<strong>related</strong> macular degeneration. Arch Ophthalmol 2002;120:1029–38.35. Ali F, Chan WC, Stevenson MR, Muldrew KA, Chakravarthy U. Morphometric analysisof angiograms of exudative lesions in <strong>age</strong>-<strong>related</strong> macular degeneration. Arch Ophthalmol2004;122:710–15.36. Hogg R, Curry E, Muldrew A, Winder J, Stevenson M, McClure M, et al. Identification oflesion components that influence visual function in <strong>age</strong>-<strong>related</strong> macular degeneration. Br JOphthalmol 2003;87:609–14.37. <strong>Verteporfin</strong> Roundtable 2000 and 2001 Participants. Treatment of <strong>age</strong>-<strong>related</strong> maculardegeneration with <strong>photodynamic</strong> <strong>therapy</strong> (TAP) study group principal investigators;<strong>Verteporfin</strong> in <strong>photodynamic</strong> <strong>therapy</strong> (VIP) study group principal investigators.Guidelines <strong>for</strong> using verteporfin (visudyne) in <strong>photodynamic</strong> <strong>therapy</strong> to treat choroidal<strong>neovascular</strong>ization due to <strong>age</strong>-<strong>related</strong> macular degeneration and other causes. Retina2002;22:6–18.38. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment DiabeticRetinopathy Study design and baseline patient characteristics: ETDRS Report Number 7.Ophthalmology 1991;98:741–56.39. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart <strong>for</strong> measuring contrastsensitivity. Clin Vis Sci 1988;2:187–99.40. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36):I.Conceptual framework and item selection. Med Care 1992;30:473–83.41. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In Higgins JPT, Green S,editors. Cochrane handbook <strong>for</strong> systematic reviews of interventions. Chichester: John Wiley;2008. pp. 187–242. URL: www.cochrane-handbook.org (accessed 31 August 2010).42. Stevenson MR, Hart PM, Chakravarthy U, Mackenzie G, Bird AC, Owens SL, et al. Subfovealradio<strong>therapy</strong> study. Visual functioning and quality of life in a randomised controlled clinicaltrial SFRADS report 2. Br J Ophthalmol 2005;89:1045–51.43. Desai P, Minassian DC, Reidy A. National cataract survey 1997–8: a report of the results ofthe clinical outcomes. Br J Ophthalmol 1999;83:1336–40.44. Browne JP, Hopkins C, Slack R, Topham J, Reeves BC, Lund V, et al. Health-<strong>related</strong> quality oflife after polypectomy with and without additional surgery. Laryngoscope 2006;116:297–302.45. Langham J, Reeves BC, Lindsay KW, van der Meulen JH, Kirkpatrick PJ, Gholkar AR, et al.Variation in outcome after subarachnoid hemorrh<strong>age</strong>: a study of neurosurgical units in UKand Ireland. Stroke 2009;40:111–18.46. Maguire MG, Klein ML, Chamberlin JA. Recurrent choroidal <strong>neovascular</strong>ization after argonlaser photocoagulation <strong>for</strong> <strong>neovascular</strong> maculopathy. Macular Photocoagulation StudyGroup. Arch Ophthalmol 1986;104:503–12.47. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-<strong>related</strong> macular degeneration andsmoking. The Rotterdam Study. Arch Ophthalmol 1996;114:1193–6.48. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and <strong>age</strong>-<strong>related</strong>macular degeneration: a review of association. Eye 2005;19:935–44.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State <strong>for</strong> Health.
Change language